{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Study intervention may refer to the individual study interventions or the combination of', 'those study interventions. All study interventions will be administered at the approved', 'dosages.', 'The investigational study intervention DTG/3TC FDC will be supplied by ViiV', 'Healthcare/GSK as the fixed dose combination tablet. Participants randomly assigned to', 'continue CAR for up to 52 weeks will not have drug provided as clinical trial material,', 'except where provision of CAR in this specific study setting is required by country and', 'local regulations. The individual components of CAR will be recorded on the', 'Concomitant ART Therapy (ConART) eCRF page. For participants randomized to CAR,', 'provisions will be in place, as needed and after discussion with the study team, to assist', 'participants in obtaining their CAR during the study.', 'DTG/3TC FDC must be stored in a secure area under the appropriate physical conditions', 'for the product. Access to and dispensing of the DTG/3TC FDC will be limited to the', 'investigator and authorized site staff. Study intervention must be dispensed or', 'administered only to participants enrolled in the study and in accordance with the', 'protocol. For further details on storage, access and administration of study interventions,', 'refer to the SRM.', '44']['2017N331008_06', 'CONFIDENTIAL', '208090', '6.1.', 'Study Interventions Administered', 'Table 1', 'Study Interventions', 'Intervention Name:', 'DTG/3TC FDC', 'CAR', 'Dosage formulation:', 'White, oval, film-coated', 'Refer to product label', 'tablets', 'Unit dose strength(s)/Dosage', '50mg/300mg', 'Refer to product label', 'level(s):', 'Route of Administration', 'oral', 'Refer to product label', 'Dosing instructions:', 'Take one tablet daily', 'Refer to product label', 'Packaging and Labelling', 'The tablets are packed in high', 'Refer to product label', 'density polyethylene (HDPE)', 'bottles with induction seals', 'and child-resistant closures.', 'Each 60mL bottle contains 30', 'tablets and a 2 gram silica', 'gel desiccant. Each bottle', 'will be labelled as required', 'per country requirement.', 'Manufacturer', 'GSK', 'Refer to product label', '6.2.', 'Dose Modification', 'No dose adjustments are permitted in this study for DTG/3TC FDC or for CAR.', '6.3.', 'Method of Treatment Assignment', 'Informed consent must be obtained prior to any study procedures, including any', 'screening assessment.', 'Participants will be assigned to study intervention in accordance with the computer-', 'generated randomization schedule. The central randomization schedule will be generated', 'by Pharmaceutical Product Development (PPD) using a validated SAS developed', 'program.', '45']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Randomization and study intervention assignment will be facilitated by the interactive', 'voice/web recognition system (IVRS/IWRS). Following confirmation of fulfilment of', 'study entry criteria, study site personnel will be required to contact the IVRS/IWRS to', 'register participants. Participants will be randomized in a 1:1 ratio to DTG/3TC FDC or', 'the CAR arm, in accordance with the computer-generated randomization schedule. To', 'control for treatment related factors that may impact study outcomes, randomization will', 'be stratified by baseline third agent class (protease inhibitor [PI], integrase inhibitor', '[INI], or non-nucleoside reverse transcriptase inhibitor [NNRTI]). Each participant will', \"be assigned a unique identifier (designating the participant's randomization code) and a\", 'unique treatment number which matches the randomized treatment assignment.', 'Participants who are randomly assigned into the trial and subsequently withdrawn may', 'not be rescreened. Once a randomisation number has been assigned it must not be', 're-assigned.', '6.4.', 'Blinding', 'This is an open-label study; potential bias will be reduced by the following steps: central', 'randomization. No summaries of the study data according to actual randomized treatment', 'groups will be available to sponsor staff prior to the planned Week 24 preliminary', 'analysis. Public presentation of the Week 24 analysis will not be done until after the last', 'participant completes their last visit for the primary Week 48 analysis.', '6.5.', 'Preparation/Handling/Storage/Accountability', 'No special preparation of study intervention is required.', 'The investigator or designee must confirm appropriate temperature conditions have', 'been maintained during transit for all study intervention received and any', 'discrepancies are reported and resolved before use of the study intervention.', 'Only participants enrolled in the study may receive study intervention and only', 'authorized site staff may supply or administer study intervention. All study', 'interventions must be stored in a secure, environmentally controlled, and monitored', '(manual or automated) area in accordance with the labeled storage conditions with', 'access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where applicable)', 'is responsible for study intervention accountability, reconciliation, and record', 'maintenance (i.e., receipt, reconciliation, and final disposition records).', 'Further guidance and information for the final disposition of unused study', 'intervention are provided in the SRM.', 'Under normal conditions of handling and administration, study intervention is not', 'expected to pose significant safety risks to site staff.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing occupational', 'hazards and recommended handling precautions either will be provided to the', 'investigator, where this is required by local laws, or is available upon request from', 'ViiV/GSK.', '46']\n\n###\n\n", "completion": "END"}